A new vaccine, ImMucin, has been developed to treat a specific molecule which is present in 90 percent on all types of cancer. Researchers found that all their treated patients had greater immunity to the disease after receiving the drug.
In essence, the vaccine works by priming the body's immune system which aims to prevent cancer diseases. "ImMucin educates the patient's immune system to identify and destroy cancer cells where the MUC1 marker is present," according to drug makers from Vaxil Biotherapeutics and Tel Aviv University.
Although the MUC1 protein marker is present in all cells of the body, the vaccine only initiates the defense mechanism for cells (particularly on cancer cells) which have large amounts of MUC1 as compared to normal cells which has too low concentrations of the marker.
The clinical trial was held at the Hadassah Medical Centre in Jerusalem which consisted 10 patients all diagnosed with multiple myeloma, a unique blood cancer that affects the plasma cells of the bone marrow. Researchers have stated that seven of the patients had greater immunity against the cancer cells, wherein three of them in the study are now free of the disease.
"ImMucin generated a robust and specific immune response in all patients which was observed after only 2 to 4 doses of the vaccine out of a maximum 12 doses." said the researchers.
Results still needs to be published, but when the findings are confirmed in future trials, the vaccine will be in the market in the next six years.